Photo: Teva
A US district court has dismissed Teva’s case against the US Food and Drug Administration (FDA) aimed at stopping the administration from approving generic versions of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, Copaxone, generics, US District Court for the District of Columbia, Mylan